Skip to main content
main-content

Metformin

News

24-09-2019 | Metformin | News

More evidence of cardiovascular benefits of metformin reported

Research published in JAMA supports a beneficial cardiovascular safety profile for metformin relative to sulfonylureas in people with mild or moderate kidney dysfunction.

18-09-2019 | Vildagliptin | EASD 2019 | News

Trial results VERIFY first-line combination therapy for type 2 diabetes

Upfront combination therapy with vildagliptin and metformin is more durable than metformin alone, and appears to have a legacy effect, report the VERIFY investigators.

06-08-2019 | Metformin | Highlight | News

Support for metformin cardioprotective effect

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

Read more

Opinion

14-12-2017 | Guidelines | Editorial | Article

What is new in the 2018 American Diabetes Association Standards of Medical Care in Diabetes?

Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2018's ADA Standards of Care update. 

22-11-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

08-05-2017 | Metformin | Editorial | Article

Metformin: What is new with this old medication?

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.

In depth

30-09-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

15-01-2018 | Type 1 diabetes | Hot topic review | Article

What do we know about adjunct non-insulin medications in type 1 diabetes?

medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.

Journal articles and book chapters

05-09-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

17-08-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

23-07-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

Case reports

28-05-2018 | Lifestyle interventions | Case report | Article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

29-03-2018 | Pregnancy | Case report | Article

Empagliflozin, metformin, and insulin degludec, during pregnancy: A case report

Formoso G et al. Acta Diabetol 2018; 55: 759. doi: 10.1007/s00592-018-1134-y

Image Credits